# Patent

## Title
Coatings for implantable medical devices incorporating chemically-bound polymers and oligomers of L-arginine

## Abstract

A coating for an implantable medical device is disclosed. The coating comprises a polymer and an amino acid chemically bonded, attached or conjugated to the polymer. In one embodiment, the coating can include a therapeutic substance. In lieu of bonding the amino acid to the polymer, the amino acid can be chemically bonded to the therapeutic substance or both the substance and the polymer. The amino acid can be polymers and/or oligomers of L-arginine, and copolymers of L-arginine with lysine. The coating can optionally include a nitric oxide donor, such as diazenium diolate type nitric oxide donors, chemically conjugated to the amino acid.

## Background
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to the field of implantable medical devices, such as stents. More particularly, this invention is directed to coatings for devices, which include chemically bound polymers and/or oligomers of L-arginine.
2. Description of the Background
In the field of medical technology, there is frequently a necessity to administer a therapeutic substance locally. To provide an efficacious concentration to the treatment site, systemic administration of medication often produces adverse or toxic side effect for the patient. Local delivery is a preferred method in that smaller total levels of medication are administered in comparison to systemic dosages, but are concentrated at a specific site. Thus, local delivery produces fewer side effects and achieves more effective results. For the treatment of vascular occlusions, such as restenosis, stents are being modified to administer therapeutic substances locally. One method of medicating a stent is with the use of a polymer coating impregnated with a therapeutic substance. The coating allows for the sustained release of the substance at the treatment site. L-arginine, or polypeptide oligomeric derivatives or analogs thereof, for example, those containing 5 to 20 amino acid units are one example of a therapeutic substance that can be used in conjunction with a stent.
L-arginine is a known precursor of endothelium derived nitric oxide (NO). NO is synthesized from L-arginine, or its polymeric and/or oligomeric derivatives, by the enzyme NO synthase, a homodimeric flavo-hemoprotein that catalyzes the 5-electron oxidation of L-arginine to produce NO and L-citrulline. Among other therapeutic properties, NO relaxes vascular smooth muscle cells and inhibits the cells' proliferation. Inhibition of proliferation of vascular smooth muscle cells is believed to contribute to the reduction or elimination of restenosis.
U.S. Pat. No. 5,861,168 to Cooke et al. teach that NO activity is reduced after vascular injury. Cooke et al. also teach that administering L-arginine as the NO precursor helps to restore vascular NO activity in patients with endothelial vasodilator dysfunction due to restenosis.
However, introducing L-arginine into a stent coating by mere mechanical or physical blending with a polymer may be insufficient to achieve maximum therapeutic results. In other words, L-arginine will have a tendency to be released quickly when the stent coating is brought into contact with body fluids such as blood. The short residence time of the compound may be insufficient for the effective treatment of the patient. Accordingly, increasing the residence time of L-arginine at the implantation site is desired.
In addition, the amount of NO generated by L-arginine, or its polymers and/or oligomers, may be insufficient to achieve the best therapeutic results. Consequently, it is desirable to obtain an additional amount of NO upon decomposition of L-arginine, or its polymers and/or oligomers, caused by NO synthase oxygenase enzyme. Accordingly, it is desirable to incorporate an additional source of NO into the molecule of L-arginine, or its polymers and/or oligomers.
SUMMARY
In accordance with one embodiment of the invention, a coating for an implantable medical device, such as a stent, is provided. The coating comprises a polymer and an amino acid chemically bonded, attached or conjugated to the polymer. The amino acid includes polymers and/or oligomers of L-arginine, and copolymers of L-arginine with lysine. The oligomers of L-arginine can be a heptamer or a nonamer. The polymer can have at least one reactive group, for example, a hydroxyl, a carboxyl, or a glycidyl group. Representative examples of polymers include poly(ethylene-co-vinyl alcohol), poly(butyl methacrylate-co-2-hydroxyethyl methacrylate), poly(ethylene glycol), poly(ethylene-co-acrylic acid), poly(ethylene-co-glycidyl methacrylate), and mixtures thereof. In one embodiment, a therapeutic substance can be dispersed in the polymer for inhibiting or eliminating restenosis of a blood vessel. In another embodiment, a nitric oxide donor can be chemically conjugated to the amino acid. The nitric oxide donor can comprise a diazenium diolate type nitric oxide donor, wherein the diazenium diolate type donor can be spermine diazenium diolate, 1-{N-methyl-N-[6-(N-methylammonio)hexyl]amino} diazen-1-ium-1,2-diolate, Z-1-[N-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate and mixtures thereof.
In accordance with another embodiment of the invention, a coating for an implantable medical device, such as a stent, is provided. The coating comprises a polymer; a therapeutic substance contained by the polymer for the sustained release of the therapeutic substance; and, an amino acid chemically bonded, attached or conjugated to the polymer, the therapeutic substance, or both. The therapeutic substance can be, for example, rapamycin or analogs or derivatives thereof, taxol or analogs or derivatives thereof, or anti-sense oligonucleotides.
In accordance with another embodiment of the invention a method of coating an implantable medical device, such as a stent, is provided. The method comprises forming a coating on the device, the coating comprising a polymer and an amino acid chemically bonded or conjugated to the polymer.


DETAILED DESCRIPTION
L-arginine, commonly abbreviated as “R” or “Arg,” is an amino acid having a formula NH═C(NH2—NH—CH2—CH2—CH2—CH(NH2)—COOH. L-arginine is also known as 2-amino-5-guanidinovaleric acid. Polymers and/or oligomers of L-arginine that can be used are herein referred to as “PArg” and comprise a plurality of repeating monomeric amino acid units connected with peptide bonds. The PArg polymers and/or oligomers have a general formula H[NH—CHX—CO]p—OH, where “p” can be within a range of 5 and 1,000, such as for example, within a range of between 5 and 20. In one embodiment, a heptamer (designated R7) or a nonamer (R9), having p=7 and p=9, respectively, can be used. In the formula of PArg, “X” is a 1-guanidinopropyl radical having the structure —CH2—CH2—NH2—NH—C(NH2)═NH. The terms “polymers and/or oligomers of L-arginine,” and “PArg” are intended to include L-arginine in both its polymeric and oligomeric form.
The family of polymers that can be used to make coatings for medical devices according to the embodiments of the present invention can be characterized by the presence of a polyolefin backbone, pendant on which are reactive groups, for example hydroxyl, glycidyl, carboxyl, and/or other suitable reactive groups. PArg, such as R7 or R9 can be chemically bonded or attached to the polymer's backbone utilizing one or more of the pendant reactive groups, for example the hydroxyl groups. A copolymer of ethylene and vinyl alcohol (EVOH) is one example of a polymer on which PArg, such as R7 or R9, can be chemically grafted. Poly(ethylene-co-vinyl alcohol) is also known under the trade name EVAL and is distributed commercially by Aldrich Chemical Company of Milwaukee, Wis. EVAL is also manufactured by EVAL Company of America of Lisle, Ill. EVAL has the general formula —[CH2—CH2]m—[CH2—CH(OH)]n—. EVAL is a product of hydrolysis of ethylene-vinyl acetate copolymers. EVAL may also be a terpolymer and may include up to 5% (molar) of units derived from styrene, propylene and other suitable unsaturated monomers.
Other representative examples of polymers include, but are not limited to, poly(butylmethacrylate-co-2-hydroxyethyl methacrylate) (p(BMA-HEMA)), poly(butylmethacrylate)-co-poly(2-hydroxyethyl methacrylate (PBMA-PHEMA), poly(ethylene glycol) (PEG), poly(ethylene-co-acrylic acid)(PEAA), poly(ethylene-co-glycidyl methacrylate)(PEGMA), EVAL-PEG blends, and other mixtures and combinations thereof.
PArg can be chemically bonded to one or a blend of polymers by covalent conjugation of the PArg to the polymer. The functional groups of the polymers, such as the hydroxyl groups in EVAL, PEG or PHEMA, the carboxyl groups in PEAA, or the glycidyl groups in PEGMA, are used as sites for the conjugation. The grafting of PArg to the polymer can be conducted directly on the stent or the grafting to the polymer can be performed first, and the product is then applied on the stent to form a coating.
In accordance with another embodiment, instead of PArg, a copolymer of L-arginine with another amino acid can be chemically bonded the polymer or combination of polymers. One example of an amino acid that can be combined with L-arginine by co-polycondensation is L-lysine, also known as 2,6-diaminohexanoic acid, having the formula NH2—(CH2)4—CH(NH2)—COOH.
A co-peptide of L-arginine and L-lysine can be prepared using standard methods of peptide synthesis known to those having ordinary skill in the art. If L-lysine is used, in the L-arginine-L-lysine co-peptide, the molar ratio between the units derived from L-lysine and L-arginine can be, for example, about 1:7; that is, for about every 7 L-arginine-derived units, there appears 1 L-lysine-derived unit.
In accordance with another embodiment, an additional source of NO can be chemically incorporated into PArg. This is achieved by modifying PArg with a molecule-source of NO, followed by grafting of the modified PArg to the backbone of the polymer. Alternatively, unmodified PArg can be first grafted to the polymer, followed by reacting with the molecule-source of NO. Sources of additional NO include diazenium diolate type nitric oxide donors, which are adducts of nitric oxide with nucleophilic amines. Diazenium diolates, also known as “NONOates,” are highly biologically compatible, and in slightly acidic medium they spontaneously release NO. One example of diazenium diolate that can be used is spermine diazenium diolate (SDD).
An aliphatic NONOate, SDD, or 1,3-propanediamine, N-{4-[1-(3-aminopropyl)-2-hydroxy-2-nitrosohydrazino] butyl}-diazen-1-ium-1,2-diolate has the formula NH2(CH2)3—N[N+(O)—(N−—OH)]—(CH2)4—NH—(CH2)3—NH2 and is manufactured by Molecular Probes, Inc. of Eugene, Oreg. Alternatively, other diazenium diolate-type NO donors can be used. Examples of such alternative diazenium diolate-type NO donors include such compounds as, for instance, 1-{N-methyl-N-[6-(N-methylammonio)hexyl]amino}diazen-1-ium-1,2-diolate having the formula CH3—N+H2—(CH2)6—N(CH3)—N+(O−)═N—O− (MAHMA-NO), or Z-1-[N-(2-Aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate having the formula O—N+[N(CH2CH2NH2)CH2CH2N+H3]═N—O− (DETA-NO). MAHMA-NO and DETA-NO can be obtained from Cayman Chemical Co. of Ann Arbor, Mich.
In accordance with another embodiment of the invention, a therapeutic substance or a drug can be incorporated into the polymeric coating. The therapeutic substance can include any substance capable of exerting a therapeutic or prophylactic effect for the patient. For example, the therapeutic substance can be for inhibit the activity of vascular smooth muscle cells. The substance can be directed at inhibiting abnormal or inappropriate migration and/or proliferation of smooth muscle cells to inhibit restenosis. The drug may include small molecule drugs, peptides, proteins, oligonucleotides, or double-stranded DNA.
Examples of therapeutic substances include antiproliferative substances such as actinomycin D, or derivatives and analogs thereof. Synonyms of actinomycin D include dactinomycin, actinomycin IV, actinomycin I1, actinomycin X1, and actinomycin C1. The substance can also fall under the genus of antineoplastic, anti-inflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antimitotic, antibiotic, antiallergic and antioxidant substances. Examples of antineoplastics and/or antimitotics include paclitaxel, docetaxel, methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride, and mitomycin.
Examples of antiplatelets, anticoagulants, antifibrin, and antithrombins include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, and thrombin. Examples of cytostatic or antiproliferative agents include angiopeptin, angiotensin converting enzyme inhibitors such as captopril, cilazapril or lisinopril, calcium channel blockers (such as nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (ω-3- fatty acid), histamine antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug), monoclonal antibodies (such as those specific for Platelet-Derived Growth Factor (PDGF) receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), and nitric oxide. An example of an antiallergic agent is permirolast potassium.
Other therapeutic substances or agents which may be appropriate include alpha-interferon genetically engineered epithelial, endothelial, vascular smooth muscle cells, or other cells; cell cycle inhibitors such as rapamycin and its derivatives and analogs, and flavopiridol; the estrogen receptors such as estrogen, estrogen analogs, tamoxifen, and idoxifene; the retinoid receptors, such as retinal and retinoic acid; the PPAR alpha and gamma receptors such as troglitizone, rosiglitazone and pioglitazone; inhibitors of cell signaling including inhibitors of Ras and the MAP kinase cascade; inhibitors of receptor tyrosine kinases; steroid receptors such as clobetasol, dexamethasone, and derivatives or analogs thereof.
In accordance with yet another embodiment, PArg can be conjugated to the therapeutic substance, in addition to, or instead of, being conjugated to the polymer. For example, PArg can be chemically bonded or attached to rapamycin, or derivatives or analogs thereof, taxol and anti-sense oligonucleotides.
The polymer can be used to form a coating for a balloon expandable or self-expandable stent. The use of the coating is, however, not limited to stents and the coating can also be used with a variety of other medical devices. Examples of an implantable medical device, that can be used in conjunction with the embodiments of this invention include stent-grafts, grafts (e.g., aortic grafts), artificial heart valves, cerebrospinal fluid shunts, pacemaker electrodes, axius coronary shunts and endocardial leads (e.g., FINELINE and ENDOTAK, available from Guidant Corporation). The underlying structure of the device can be of virtually any design. The device can be made of a metallic material or an alloy such as, but not limited to, cobalt-chromium alloys (e.g., ELGILOY), stainless steel (316L), “MP35N,” “MP20N,” ELASTINITE (Nitinol), tantalum, tantalum-based alloys, nickel-titanium alloy, platinum, platinum-based alloys such as, e.g., platinum-iridium alloy, iridium, gold, magnesium, titanium, titanium-based alloys, zirconium-based alloys, or combinations thereof. Devices made from bioabsorbable or biostable polymers can also be used with the embodiments of the present invention. “MP35N” and “MP20N” are trade names for alloys of cobalt, nickel, chromium and molybdenum available from Standard Press Steel Co. of Jenkintown, Pa. “MP35N” consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum. “MP20N” consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum.
Embodiments of the present invention are further illustrated by the following examples.
EXAMPLE 1
R7 can be grafted to EVAL. Optionally, an NO donor, such as DETA-NO can be first conjugated to R7. EVAL with m:n ratio of 44:56 can be used. EVAL with a higher or lower ethylene content can be modified by the same methods as those discussed below. The first optional step of grafting includes conjugation of DETA-NO to R7 utilizing an amide linkage with R7 according to the following reaction scheme (I):




A variation of reaction (I) includes cross-linking of R7 with DETA-NO using a imidoester cross-linking agent, such as dimethyl adipimidate (DMA), dimethyl pimelimidate (DMP) or dimethyl 3,3′-dithiobispropionimidate (DTBP). DMA, DMP and DTBP are manufactured commercially by Pierce Corp. of Rockford, Ill.
Next, EVAL can be halogenated by phosphorous trichloride PCl3, phosphorous pentachloride PCl5 thionyl chloride SOCl2, or other appropriate halogenating agent, via EVAL's hydroxyl group. This process, a nucleophilic substitution SN2 can be schematically illustrated according to reaction (II):

—[CH2—CH2]m—[CH2—CH(OH)]n—+SOCl2→—[CH2—CH2]m—[CH2—CHCl]n+—SO2+HCl  (II)

Next, the non-protonated non-terminal primary amino groups of R7 are protected by reaction (III) with 9-fluorenylmethyl chloroformate in aqueous dioxane, where 9-fluorenylmethyl chloroformate, also known as 9-fluorenylmethyloxycarbonylchloride or FMOC-chloride, has the formula




and, reaction (III) is





where L is either H (if the optional grafting of DETA-NO shown in reaction (I) was not performed) or DETA-NO.

The reaction of esterification (IV) is carried out where the carboxyl group of the protected R7 is reacted with the halogenated EVAL obtained in reaction (II):




Finally, the product of reaction (IV) is cleaved by 50% morpholine or other appropriate amine.
As a result of the nucleophilic reaction (IV), R7 (with or without the additional source of NO) is bound or attached to EVAL by a labile ester bond. This bond is hydrolytically weak and will be broken when the stent is subjected to the body fluids. Thus, R7 will be released bringing about a desirable therapeutic effect. The reactions schemes described above are conducted under standard conditions which are known to those having ordinary skill in the art.
EXAMPLE 2
DETA-NO can be optionally grafted to R7 as shown in Example 1, reaction (I). Next, the non-protonated, non-terminal primary amino groups of R7 are protected by reaction with 9-fluorenylmethyl chloroformate in aqueous dioxane as shown in Example 1, reaction (III).
The reaction of direct esterification is then carried out, as a result of which, the carboxyl group of R7 is conjugated to EVAL in the presence of 1,3-dicyclohexylcarbodiimide (DCC) having the formula




wherein, DCC activates the carboxyl group of R7, thus facilitating the esterification reaction of nucleophilic substitution (V):





where L is defined in Example 1.

Reaction (V) is conducted under standard conditions known to those having ordinary skill in the art. An insoluble substance, N,N-dicyclohexylurea, having the formula




is a by-product of the reaction (V). Finally, the R7-EVAL conjugate, the product of reaction (V), is de-protected by a reaction with morpholine or another appropriate amine, as in Example 1.

Alternatively, the reaction of direct esterification can be carried out in the presence of dimethylaminopyridine (DMAP).
As a result of the reaction (V), R7 (with or without the additional source of NO) is bound or attached to EVAL by a labile ester bond.
EXAMPLE 3
The preparation of EVAL-R7 conjugate is similar to Example 1, but the order of steps can be different. First, the non-protonated, non-terminal primary amino groups of R7 are protected by reaction with 9-fluorenylmethyl chloroformate in aqueous dioxane as shown in Example 1, reaction (III). Next, EVAL is reacted with the protected R7. This can be accomplished using preliminarily halogenated EVAL as shown by reaction (IV), Example 1. Alternatively, a direct esterification in the presence of DCC or DMAP can be used as in Example 2.
Next, DETA-NO can be optionally grafted to R7 as shown in Example 1, reaction (I). Instead of DMA, DMP or DTBP, discussed in Example 1, a di-succinimidyl ester in a non-aqueous solvent (e.g., dimethyl acetoamide) can be used at a temperature of about 40° C. in a slightly basic medium (e.g., pH ̃7.4) to perform the cross-linking of DETA-NO with R7. Examples of suitable di-succinimidyl esters include bis(succinimidooxycarbonyloxyethyl sulfone) (BSOCOES) having the formula [M—O—C(O)—O—CH2—CH2]2—SO2, and dithiobis(succinimidyl propionate) (DTSP) having the formula [M—O—C(O)O—CH2—CH2—S—]2. In both BSOCOE and DTSP, M is a succinimide group. BSOSOES and DTSP can be obtained from Molecular Biosciences, Inc. of Boulder, Colo. DTSP is also known as the Lomant's reagent.
Finally, the R7-EVAL conjugate, the product of the above-described process, is de-protected by a reaction with morpholine or another appropriate amine, as in Example 1.
As a result, R7 (with or without the additional source of NO) is bound or attached to EVAL by a labile ester bond.
EXAMPLE 4
EVAL can be preliminarily derivatized by tosylation (treatment with tosyl chloride), or alternatively by tresylation (by reacting with tresyl chloride). Tosyl chloride is a derivative of toluene, para-toluenesulfonil chloride having the formula CH3—C6H4—SO2Cl (TsCl). The process of EVAL derivatization can be conducted directly on the stent. The following process of tosylation can be used.
A 2% (mass) solution of EVAL in dimethylacetamide (DMAC) can be sprayed on the stent and dried for 10 minutes at 80° C., and then for 1 hour at 140° C. A 3% (mass) of TsCl in dry xylene can be prepared and the coated EVAL stent can be shaken for 1 minute with 1.4 ml of the TsCl solution. 0.25 ml of 33% (mass) of pyridine in dry xylene can be added, followed by shaking for 4 hours in desiccator. The stent can then be rinsed with acetone and twice with 1 mM solution of HCl to remove the excess TsCl.
As a result, EVAL is tosylated according to reaction (VI) and tosyl group is attached to the EVAL backbone via hydroxy group to yield the toluenesulfoester:




Alternatively, tresyl chloride (2,2,2-trifluoroethanesulphonyl chloride) can be used to derivatize EVAL, according to reaction scheme (VII) and a tresyl group is attached to the EVAL backbone via hydroxy group:




Next, DETA-NO can be optionally grafted to R7 as shown in Example 1, reaction (I), followed by protecting the non-protonated, non-terminal primary amino groups of R7 by reaction with 9-fluorenylmethyl chloroformate in aqueous dioxane as shown in Example 1, reaction (III).
The protected R7 can then be added to the tosylated or tresylated EVAL, while the pH is maintained at a neutral or slightly basic level. The protected R7 is chemically quite active because its carboxyl group at pH≧7 is in the ionized (de-protonated) form, COO−. Accordingly, the protected R7 under such conditions is a stronger nucleophile than the tosylated anion on EVAL and readily enters into a reaction of nucleophilic substitution with the tosylated or tresylated EVAL in solution.
In addition, since toluenesulfonic acid is known to be a very strong acid, on par with sulfuric or hydrochloric acids, its anion, CH3—C6H4—SO3−, is an excellent leaving group in the nucleophilic substitution alkylation reaction between the protected R7 and EVAL, much better than the hydroxyl group of an underivatized EVAL.
Consequently, the tosylated EVAL obtained as described above, readily reacts with the protected R7 as schematically shown by the alkylation reaction (VIII):




where L is defined in Example 1.

The conditions under which reaction (VIII) is conducted can be determined by those having ordinary skill in the art. The reaction of tresylated EVAL and the protected R7 is similar to reaction (VIII).
Finally, the R7-EVAL conjugate, the product of reaction (VIII), is de-protected by a reaction with morpholine or another appropriate amine, as in Example 1.
As a result of the reaction (VIII), R7 (with or without the additional source of NO) is bound or attached to EVAL by a labile ester bond.
EXAMPLE 5
DETA-NO can be optionally grafted to R7 as shown in Example 1, reaction (I), followed by protecting the non-protonated amino groups of R7 by reaction with 9-fluorenylmethyl chloroformate in aqueous dioxane as shown in Example 1, reaction (III). The protected R7 is then halogenated by thionyl chloride or phosphorous tri- or pentachloride. The reaction of halogenation is similar to reaction (II) shown in Example 1, except that instead of halogenating hydroxyl groups, here the terminal carboxyl groups of the protected R7 are halogenated.
The halogenated protected R7 is then esterified by reacting with EVAL to form labile ester bonds. This esterification reaction is a mirror image of reaction (IV) described in Example 1. Finally, the R7-EVAL conjugate, the product of this esterification reaction, is de-protected by a reaction with morpholine or another appropriate amine, as in Example 1.
As a result, R7 (with or without the additional source of NO) is bonded or attached to EVAL by a labile ester bond.
While particular embodiments of the present invention have been shown and described, it will be obvious to those skilled in the art that changes and modifications can be made without departing from this invention in its broader aspects. Therefore, the appended claims are to encompass within their scope all such changes and modifications as fall within the true spirit and scope of this invention.

## Claims

1. A coating for an implantable medical device, the coating comprising a polymer and an amino acid chemically bonded to the polymer, wherein the amino acid comprises L-arginine.

2. The coating of claim 1, wherein the medical device comprises a stent.

3. A coating for an implantable medical device, the coating comprising a polymer and an amino acid chemically bonded to the polymer, wherein the amino acid comprises polymers and/or oligomers of L-arginine, or copolymers or co-peptides of L-arginine with lysine.

4. The coating of claim 3, wherein the oligomers of L-arginine include a heptamer or a nonamer.

5. The coating of claim 1, wherein the polymer has at least one reactive group.

6. The coating of claim 5, wherein the reactive group comprises a hydroxyl, a carboxyl or a glycidyl group.

7. The coating of claim 1, wherein the polymer comprises a component selected from a group consisting of poly(ethylene-co-vinyl alcohol), poly(butyl methacrylate-co-2-hydroxyethyl methacrylate), poly(ethylene glycol), poly(ethylene-co-acrylic acid), poly(ethylene-co-glycidyl methacrylate), and mixtures or combinations thereof.

8. The coating of claim 1, additionally including a therapeutic substance dispersed in the polymer effective for inhibiting or eliminating restenosis of a blood vessel.

9. The coating of claim 1, further comprising a nitric oxide donor chemically conjugated to the amino acid.

10. The coating of claim 9, wherein the nitric oxide donor comprises a diazenium diolate type nitric oxide donor.

11. The coating of claim 10, wherein the diazenium diolate type donor comprises a component selected from a group consisting of spermine diazenium diolate, 1-{N-methyl-N-[6-(N-methylammonio)hexyl]amino}diazen-1-ium-1,2-diolate, Z-1-[N-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate and mixtures thereof.

12. A coating for an implantable medical device, the coating comprising a polymer, a therapeutic substance contained by the polymer for the sustained release of the therapeutic substance and an amino acid chemically bonded, attached or conjugated to the polymer, the therapeutic substance, or both, wherein the amino acid comprises L-arginine.

13. The coating of claim 12, wherein the therapeutic substance comprises antiproliferatives rapamycin or analogs or derivatives thereof, paclitaxel or analogs or derivatives thereof, docetaxel or analogs or derivatives thereof, or anti-sense oligonucleotides.

14. The coating of claim 12, wherein the implantable medical device comprises a stent.

15. A coating for an implantable medical device, the coating comprising a polymer, a therapeutic substance contained by the polymer for the sustained release of the therapeutic substance and an amino acid chemically bonded, attached or conjugated to the polymer, the therapeutic substance, or both, wherein the amino acid comprises polymers and/or oligomers of L-arginine, or copolymers or co-peptides of L-arginine with lysine.

16. The coating of claim 15, wherein the oligomers of L-arginine include a heptamer or a nonamer.

17. The coating of claim 12, wherein the polymer has at least one reactive group comprising a component selected from a group consisting of a hydroxyl, a carboxyl or a glycidyl group.

18. The coating of claim 12, further comprising a nitric oxide donor chemically conjugated to the amino acid.

19. The coating of claim 18, wherein the nitric oxide donor comprises a diazenium diolate type nitric oxide donor.

20. A method of coating an implantable medical device, comprising forming a coating on the device, the coating comprising a polymer and an amino acid chemically bonded, attached or conjugated to the polymer, wherein the amino acid comprises L-arginine.

21. The method of claim 20, wherein the medical device comprises a stent.

22. A method of coating an implantable medical device, comprising forming a coating on the device, the coating comprising a polymer and an amino acid chemically bonded attached or conjugated to the polymer, wherein the amino acid comprises polymers and/or oligomers of L-arginine, or copolymers or co-peptides of L-arginine with lysine.

23. The method of claim 22, wherein the oligomers of L-arginine include a heptamer or a nonamer.

24. The method of claim 20, additionally including a therapeutic substance dispersed in the polymer effective for inhibiting or eliminating restenosis of a blood vessel.

25. The method of claim 20, wherein the polymer has at least one reactive group.

26. The method of claim 25, wherein the reactive group comprises a component selected from a group consisting of a hydroxyl, a carboxyl or a glycidyl group.